Reconstitution of T cell immunity against EBV in the immunocompromised host by adoptive transfer of peptide-stimulated T cells after allogeneic stem cell transplantation
Rattachement africain : de, ca. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Reconstitution of T cell repertoire after allogeneic stem cell transplantation is a long and often incomplete process. As a result, reactivation of Epstein-Barr virus (EBV) is a frequent complication that may be treated by adoptive transfer of donor-derived EBV-specific T cells. We generated donor-derived EBV-specific T cells by peptide stimulation and adoptively transferred them to a patient with angioimmunoblastic T-cell lymphoma (AITL), who had developed persisting high titers of EBV concomitant to relapse after transplantation. T cell receptor beta (TCRβ) deep sequencing showed that the T cell repertoire of the patient early after transplantation (day 60) was strongly reduced and only very low numbers of EBV-specific T cells were detectable. Manufacturing and in vitro expansion of donor-derived EBV-specific T cells resulted in enrichment of EBV epitope-specific, HLA-restricted T cells. Monitoring after adoptive transfer revealed that the dominant TCR sequences from peptide-stimulated T cells persisted long-term and established an EBV-specific TCR clonotype repertoire in the host, with many of the EBV-specific TCRs present in the donor. This reconstituted repertoire was associated with immunological control of EBV and with lack of further AITL relapse. Author summary A characteristic feature of all herpesviruses is their persistence in the host’s body after primary infection. Hence, the host’s immune system is confronted with the problem to control these viruses life-long. Well-known representative of the herpesvirus group are the classic Herpes-Simplex Virus (HSV-1) and Varicella Zoster Virus (VZV, causing chicken pox); a less known representative is Epstein Barr Virus (EBV, causing mononucleosis). When the immune system is severely compromised, for example after stem cell transplantation from a foreign (allogeneic) donor, these viruses can reappear, as they are already in the host’s body. Especially EBV cause life-threatening complications after stem cell transplantation and only reinforcement of the host’s immune system can reestablish viral control. Here we show that ex vivo manufactured EBV-specific T cells can reestablish long-term control of EBV and that these cells persist in the host’s body over months. These results give us a better understanding of viral immune reconstitution post-transplant and of clinically-relevant T cell populations against EBV.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Reconstitution of T cell immunity against EBV in the immunocompromised host by adoptive transfer of peptide-stimulated T cells after allogeneic stem cell transplantation
- Date Crossref
- 17/12/2021
- Éditeur
- openRxiv
- Type
- posted-content
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Humboldt-Universität zu Berlin pays non établi dans la noticeUniversité ou école supérieure
-
Freie Universität Berlin pays non établi dans la noticeUniversité ou école supérieure
-
Charité - Universitätsmedizin Berlin pays non établi dans la noticeÉtablissement de santé
-
Universitätsklinikum Erlangen pays non établi dans la noticeÉtablissement de santé
-
LMU Klinikum pays non établi dans la noticeÉtablissement de santé
-
German Center for Infection Research pays non établi dans la noticeStructure de recherche
-
Ludwig-Maximilians-Universität München pays non établi dans la noticeUniversité ou école supérieure
-
Princess Margaret Cancer Centre pays non établi dans la noticeÉtablissement de santé
-
Department of Hematology pays non établi dans la noticeInstitution
-
Institute of Pathology pays non établi dans la noticeStructure de recherche
-
University Hospital Erlangen Department of Internal Medicine 5 – Hematology/Oncology pays non établi dans la noticeUniversité ou école supérieure
-
HS Diagnomics GmbH pays non établi dans la noticeEntreprise
Humboldt-Universität zu Berlin, Freie Universität Berlin et Charité - Universitätsmedizin Berlin, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.